Press releases
Find out more about Ferring latest announcements.
Press releases
-
Ferring Receives Approval from U.S. FDA for Adstiladrin for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
-Ferring’s novel adenovirus vector-based gene therapy Adstiladrin® (nadofaragene firadenovec-vncg) is the first gene therapy approved for bladder cancer Efficacy and safety of Adstiladrin supported by Phase 3 results demonstrating that more than half of patients (51% of CIS ± Ta/T1 cohort) achieved a complete response (CR) at three months and of these, 46% continued to remain free of high-grade recurrence […]
-
Ferring Receives U.S. FDA Approval for REBYOTA™ (fecal microbiota, live-jslm) – A Novel First-in-Class Microbiota-Based Live Biotherapeutic
-Ferring’s novel first-in-class REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI The safety and efficacy of REBYOTA was studied in the largest clinical trial program in the field of microbiome-based therapeutics, including five clinical trials with more than 1,000 participants Recurrent […]
-
Ferring Appreciates Ongoing Support from New Jersey and Minnesota as Both States Issue Proclamations Recognizing November as C. Difficile Infection Awareness Month
-Parsippany, NJ, USA – November 28, 2022 – Ferring Pharmaceuticals appreciates the continued support from New Jersey and Minnesota as both states recognize November as Clostridioides difficile (C. diff) Infection Awareness Month. This is the third year in a row that the offices of Governor Phil Murphy (New Jersey) and Governor Tim Walz (Minnesota) issued the proclamations that underscore the severity of […]